Therapy Detail

Therapy Name CUDC-101
Synonym
Therapy Description

CUDC-101 is a small-molecule inhibitor of EGFR, ERBB2 (HER2), and class I and II HDACs, which has demonstrated activity in EGFR-inhibitor resistant tumor cell lines (PMID: 20388807, PMID: 23536719).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
CUDC-101 EGFR Inhibitor (Pan) 42 HDAC Inhibitor 35 HER2 Inhibitor 21 CUDC-101 is a small-molecule inhibitor of EGFR, ERBB2 (HER2), and class I and II HDACs, which has demonstrated activity in EGFR-inhibitor resistant tumor cell lines (PMID: 20388807, PMID: 23536719).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown stomach cancer not applicable CUDC-101 Phase I Actionable In a Phase I trial, a gastric cancer patient treated with CUDC-101 demonstrated a partial response for 57 days, in which the tumor regressed by 56% (PMID: 25107918). 25107918
ERBB2 over exp Her2-receptor positive breast cancer sensitive CUDC-101 Phase I Actionable In a Phase I clinical trial, a breast cancer patient with ERBB2 (HER2) over expression that had progressed on Herceptin (trastuzumab) demonstrated stable disease for more than 12 weeks following treatment with CUDC-101 (PMID: 25107918). 25107918
Clinical Trial Phase Therapies Title Recruitment Status